Zoetis ZTS 深 滬
已收盤 08-07 16:00:00 美东时间
72.66
-4.610
-5.97%
華盛通- 最 高79.25
- 今 開77.92
- 成交量 1278.25万股
- 最 低 72.19
- 昨 收 77.27
- 總市值 304.61亿
- 52周最高 158.39
- 市盈率 靜 12.06
- 換手率 3.05%
- 52周最低 70.94
- 委 比 -23.66%
- 總股本 4.19亿
- 歷史最高 241.152
- 量 比 1.40
- 振 幅 9.14%
- 歷史最低 15.781
- 每 手 1
- 風險率 25.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Major healthcare heavyweights, including Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five c...
08-08 23:15
JP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $115
JP Morgan analyst Chris Schott maintains Zoetis (NYSE:ZTS) with a Overweight and lowers the price target from $130 to $115.
08-08 02:28
“大空头”伯里再出手：做空甲骨文(ORCL.US)和Nebius(NBIS.US) 警惕科技及云行业表外杠杆风险
“大空头”迈克尔·伯里周四宣布做空甲骨文(ORCL.US)和Nebius(NBIS.US)，并警告称，科技与云计算行业由表外承诺带来的杠杆风险正在持续抬升。 伯...
08-07 19:29
Michael Burry takes bearish bets on Oracle, Nebius
Michael Burry on Thursday disclosed two short positions, warning of rising leverage risks linked to off-balance-sheet commitments across the technology and cloud sectors. Burry said he has shorted sha...
08-07 18:11
财报速睇 | Zoetis 2026财年Q2营收24.68亿美元，同比下降0.2%；归母净利润6.91亿美元，同比下滑4.8%
华盛资讯8月7日讯，Zoetis公布2026财年Q2业绩，公司Q2营收24.68亿美元，同比下降0.2%，归母净利润6.91亿美元，同比下滑4.8%。
08-07 02:49
William Blair Downgrades Zoetis to Market Perform
William Blair analyst Brandon Vazquez downgrades Zoetis (NYSE:ZTS) from Outperform to Market Perform.
08-07 00:39
Zoetis shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
Zoetis shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
08-06 23:49
财报速睇 | Zoetis 2026财年Q2营收24.68亿美元，同比下降0.2%；归母净利润6.91亿美元，同比下滑4.8%
华盛资讯8月6日讯，Zoetis公布2026财年Q2业绩，公司Q2营收24.68亿美元，同比下降0.2%，归母净利润6.91亿美元，同比下滑4.8%。
08-06 21:25
Insmed Inc Stock (INSM) Moved Up by 31.83% on Aug 6: Key Drivers Unveiled
• Insmed shares rose following positive clinical trial data and potential acquisition interest. • Analysts revised revenue models, setting an average price target of $196.74. • Technical indicators show a sell signal with the stock currently in oversold territory.
08-06 19:15
